Curis Inc
$ 1.08
-0.92%
24 Feb - close price
- Market Cap 14,925,200 USD
- Current Price $ 1.08
- High / Low $ 1.16 / 1.08
- Stock P/E N/A
- Book Value -1.15
- EPS -3.30
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -29.51 %
- 52 Week High 3.18
- 52 Week Low 0.77
About
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-03-31 | 2024-11-01 | 2024-08-01 | 2024-05-07 | 2024-02-08 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-13 |
| Reported EPS | -0.49 | -0.68 | -1.2538 | -1.25 | -1.7 | -2.03 | -2.05 | -2.03 | -2.13 | -0.12 | -0.12 | -0.12 |
| Estimated EPS | -1.31 | -1.24 | -1.2633 | -0.99 | -1.84 | -1.67 | -2.12 | -2.11 | -2.33 | -0.12 | -0.1 | -0.13 |
| Surprise | 0.82 | 0.56 | 0.0095 | -0.26 | 0.14 | -0.36 | 0.07 | 0.08 | 0.2 | 0 | -0.02 | 0.01 |
| Surprise Percentage | 62.5954% | 45.1613% | 0.752% | -26.2626% | 7.6087% | -21.5569% | 3.3019% | 3.7915% | 8.5837% | 0% | -20% | 7.6923% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.59 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRIS
2026-02-19 21:26:41
Curis, Inc. is holding a virtual special stockholder meeting on March 17, 2026, to vote on significant capital and compensation proposals. These proposals include increasing authorized capital stock, approving the issuance of up to 26,926,675 shares related to Series B preferred stock conversion, and up to 80,780,025 shares from PIPE financing warrants, all at a $0.75 exercise price. The company is also seeking approval for a new 2026 Incentive Plan.
2026-02-13 05:57:53
A recent SEC filing reveals that certain shareholders of biopharmaceutical company Curis Inc intend to resell up to 107,706,700 ordinary shares in an irregular, batch-by-batch manner. These sales are driven by individual financial planning and do not reflect changes in the company's fundamentals. While large-scale resales could impact short-term liquidity, the long-term value assessment should consider Curis Inc.'s R&D progress and industry trends, with transactions conducted under securities regulations like Rule 144.
2026-02-09 22:58:35
Curis Inc. (NASDAQ:CRIS) has announced it has regained compliance with Nasdaq listing standards and will now enter a one-year monitoring period. This positive development follows a significant 11.1% stock return over the last week, despite an overall 69.9% decline in the past year. The company recently closed a private placement financing deal worth up to $80.8 million, earmarked for the development of emavusertib.
2026-02-09 21:58:35
Curis, Inc. is calling a virtual special stockholder meeting on March 17, 2026, to approve a significant increase in authorized capital stock, the conversion of Series B preferred stock, and the exercise of warrants from a January 2026 PIPE financing. Stockholders will also vote on a new 2026 Incentive Plan. Failure to approve these proposals would limit Curis's access to capital, restrict future equity issuances, and necessitate repeated stockholder meetings, while approval could lead to substantial potential equity dilution for existing shareholders.
2026-01-15 16:59:36
Curis Inc. (CRIS) has initiated a new Phase 2 study for emavusertib in combination with an approved Bruton tyrosine kinase inhibitor (BTKi) to treat patients with chronic lymphocytic leukemia and other B-cell malignancies, particularly those whose disease has relapsed or shows partial response to BTKi therapy. This trial aims to address the unmet need for more durable treatment options in BTKi-exposed CLL patients. While investor sentiment impact may be modest in the short term due to the early stage of the trial and lack of near-term data, it reinforces Curis's focus on emavusertib as a key asset for long-term growth in blood cancers.
2026-01-10 02:15:13
Curis, Inc. (NASDAQ:CRIS) has closed a private placement financing expected to provide up to $80.8 million in gross proceeds, with an initial $20.2 million already secured. This funding comes as the biotech firm, which has a market cap of $10.99 million and negative EBITDA, continues clinical evaluations for its drug emavusertib. The financing is supported by healthcare-focused institutional investors and company insiders to advance the development of its key therapeutic candidates.
